- Home
- / Spago Nanomedical
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Spago Nanomedical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
KR437 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 20, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.0K | 342.0K | 660.0K | 1.1M | 1.2M | 1.9M | 437.0K | |
| Gross profit | 500.0K | 30.0K | 589.0K | 902.0K | 1.3M | 4.7M | 5.7M | 4.8M |
| Gross profit margin, % | 389.4% | 299.0% | 1103.4% | |||||
| Operating expense total | 11.1M | 19.8M | 19.2M | 39.7M | 40.1M | 46.9M | 38.8M | 31.6M |
| Depreciation and amortization | 376.0K | 357.0K | 362.0K | 376.0K | 356.0K | 281.0K | 312.0K | 167.0K |
| EBITDA | (10.6M) | (19.8M) | (18.6M) | (38.8M) | (38.7M) | (42.2M) | (33.1M) | (26.8M) |
| EBITDA margin, % | -3509.9% | -1730.4% | -6127.5% | |||||
| EBIT | (11.0M) | (20.1M) | (19.0M) | (39.2M) | (39.1M) | (42.5M) | (33.4M) | (26.9M) |
| EBIT margin, % | -3533.3% | -1746.7% | -6165.7% | |||||
| Interest income | 34.0K | |||||||
| Pre tax profit | (11.1M) | (20.2M) | (18.9M) | (39.1M) | (39.2M) | (42.2M) | (32.5M) | (26.6M) |
| Net Income | (11.1M) | (20.2M) | (18.9M) | (39.1M) | (39.2M) | (42.2M) | (32.5M) | (26.6M) |